Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIndorenate hydrochloride
Discontinued Product
Indorenate hydrochloride (Cat. No. 2399) has been withdrawn from sale for commercial reasons.
Description: 5-HT1A, 5-HT1B and 5-HT2C agonist
Alternative Names: TR 3369
Chemical Name: α-(Aminomethyl)-5-methoxy-1H-indole-3-acetic acid methyl ester hydrochloride
Purity: ≥98% (HPLC)
Biological Activity for Indorenate hydrochloride
5-HT receptor agonist with high affinity for 5-HT1A receptors (pKd = 7.8) and lower affinity for 5-HT1B and 5-HT2C receptors (pKd values are 5.44 and 6.49 respectively). Possesses anti-hypertensive, anxiolytic and anorectic activity in vivo.
Technical Data for Indorenate hydrochloride
| M. Wt | 284.74 |
| Formula | C13H16N2O3.HCl |
| Storage | Desiccate at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 72318-55-9 |
| Smiles | NCC(C(OC)=O)C2=CNC1=CC=C(OC)C=C12.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Indorenate hydrochloride
References for Indorenate hydrochloride
References are publications that support the biological activity of the product.
Velazquez-Martinez et al (1999) Discriminative stimulus properties of indorenate, a serotonin agonist. J.Psychiatry Neurosci. 24 122 PMID: 10212554
Sanchez and Velazquez-Martinez (2001) Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats. J.Psychopharmacol. 15 29 PMID: 11277605
Miranda et al (2003) Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT1A/1B/2C receptors. Pharmacol.Biochem.Behav. 74 371 PMID: 12479957
View Related Products by Target
View Related Products by Product Action
Keywords: Indorenate hydrochloride, Indorenate hydrochloride supplier, 5-HT1A, 5-HT1B, 5-HT2C, agonists, Serotonin, Receptors, TR3369, TR, 3369, 2399, Tocris Bioscience
Citations for Indorenate hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Indorenate hydrochloride.
Reviews for Indorenate hydrochloride
There are currently no reviews for this product. Be the first to review Indorenate hydrochloride and earn rewards!
Have you used Indorenate hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.